Inhibition of DNA repair with MGMT pseudosubstrates: Phase i study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

British Journal of Cancer

Volumn 105, Issue 6, 2011, Pages 773-777

  Tawbi, H A ^a,b   Villaruz, L ^a,b   Tarhini, A ^a,b   Moschos, S ^a,b   Sulecki, M ^a   Viverette, F ^a   Shipe Spotloe, J ^a,b   Radkowski, R ^c   Kirkwood, J M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Theradex   (United States)

Author keywords

chemotherapy resistance; DNA repair; lomeguatrib; melanoma; MGMT pseudosubstrate

Indexed keywords

DACARBAZINE; LOMEGUATRIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DNA REPAIR; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME SUBSTRATE; FATIGUE; FEMALE; HUMAN; HYPERURICEMIA; INJECTION SITE PAIN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PURINES;

EID: 80052495942     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.285     Document Type: Article

References (33)

1. Ayi TC, Loh KC, Ali RB, Li BF (1992) Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res 52(23): 6423-6430
2. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181(3): 193-201
3. Batts ED, Maisel C, Kane D, Liu L, Fu P, O'Brien T, Remick S, Bahlis N, Gerson SL (2007) O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother Pharmacol 60(3): 415-421 (Pubitemid 46944590)
4. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58(19): 4363-4367 (Pubitemid 28450038)
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9): 809-819
6. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold Jr SC (1998) Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16(11): 3570-3575 (Pubitemid 28506770)
7. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE (2005) Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 11(21): 7861-7865 (Pubitemid 41611631)
8. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4(4): 296-307 (Pubitemid 38525285)
9. Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, Schadendorf D (2010) MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 103(6): 820-826
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997-1003 (Pubitemid 40349502)
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4): 225-249
13. Kefford RF, Thomas NP, Corrie PG, Palmer C, Abdi E, Kotasek D, Beith J, Ranson M, Mortimer P, Watson AJ, Margison GP, Middleton MR (2009) A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer 100(8): 1245-1249
14. Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12(2): 328-331 (Pubitemid 43166117)
15. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000a) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1): 158-166 (Pubitemid 30036349)
16. Middleton MR, Kelly J, Goodger S, Thatcher N, Margison GP (2000b) Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol 45(1): 15-20 (Pubitemid 30099710)
17. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A, On behalf of the EORTC Melanoma Group (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47(10): 1476-1483
18. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223
19. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462(2-3): 83-100
20. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon II JE, Bigner DD, Friedman HS (2005) Phase I trial of temozolomide plus O6-benzylgua-nine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23(28): 7178-7187
21. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon II JE, Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20(9): 2277-2283 (Pubitemid 34441654)
22. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25(18): 2540-2545 (Pubitemid 47041227)
23. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA- alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12(5): 1577-1584
24. Rigel DS (2010) Trends in dermatology: melanoma incidence. Arch Dermatol 146(3): 318
25. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE (2006) A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 58(5): 634-639 (Pubitemid 44167389)
26. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ (2000) Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 6(8): 3025-3031 (Pubitemid 30637724)
27. Schold Jr SC, Kokkinakis DM, Chang SM, Berger MS, Hess KR, Schiff D, Robins HI, Mehta MP, Fink KL, Davis RL, Prados MD (2004) O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol 6(1): 28-32 (Pubitemid 38139636)
28. Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, Kirkwood JM (1996) Carmustine and streptozotocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2(7): 1129-1134 (Pubitemid 26238442)
29. Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL, Ingalls ST, Pluda JM, Willson JK (1999) O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59(10): 2402-2410 (Pubitemid 29242289)
30. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL (2001) Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 7(8): 2309-2317 (Pubitemid 32751629)
31. Tawbi HA, Kirkwood JM (2007) Management of metastatic melanoma. Semin Oncol 34(6): 532-545 (Pubitemid 350236308)
32. Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM (2005) Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 23(30): 7646-7653 (Pubitemid 46291829)
33. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME (2007) Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 25(4): 399-404 (Pubitemid 350002988)